Stock drop nixes AMI public offering

Article

A secondary stock offering by MRI contrast developer AdvancedMagnetics was canceled due to a drop in the firm's share price,the company said earlier this month. Share prices of AdvancedMagnetics have fallen steadily this year, from $27.50 in earlyJanuary

A secondary stock offering by MRI contrast developer AdvancedMagnetics was canceled due to a drop in the firm's share price,the company said earlier this month. Share prices of AdvancedMagnetics have fallen steadily this year, from $27.50 in earlyJanuary to around $21 a share last week. Advanced Magnetics hadhoped to sell 1.35 million shares.

The Cambridge, MA, company also took a hit when it releasedsecond-quarter financial results last week. Advanced Magneticsposted a net loss for the quarter (end-March) of $2.4 millionon sales of $476,000, compared with net income of $3.3 millionand revenues of $6.2 million in the same period last year.

The company said that last year's quarterly revenues were higherdue to a $5 million licensing payment from Berlex Laboratoriesfor U.S. and Canadian rights to its Feridex IV liver agent. AdvancedMagnetics will receive another $5 million when Feridex receivesFood and Drug Administration approval. AMI received an approvableletter for Feridex earlier this year (SCAN 2/14/96).

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.